- Home
- IDR vs CLLS Comparison
IDR vs CLLS Comparison
Compare IDR & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IDR | CLLS |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.0M | 394.4M |
| IPO Year | 2000 | 2014 |
Fundamental Metrics
Financial Performance| Metric | IDR | CLLS |
|---|---|---|
| Price | $19.86 | $0.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.83 |
| AVG Volume (30 Days) | ★ 319.1K | 95.4K |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 70.15 | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $42,406,253.00 | N/A |
| Revenue This Year | $27.10 | N/A |
| Revenue Next Year | N/A | $10.70 |
| P/E Ratio | $33.92 | ★ N/A |
| Revenue Growth | ★ 64.59 | N/A |
| 52 Week Low | $20.05 | $0.88 |
| 52 Week High | $53.30 | $5.45 |
Technical Indicators
Market Signals| Indicator | IDR | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 24.30 | 21.48 |
| Support Level | N/A | N/A |
| Resistance Level | $35.52 | $2.99 |
| Average True Range (ATR) | 1.44 | 0.09 |
| MACD | -0.31 | 0.02 |
| Stochastic Oscillator | 0.37 | 15.22 |
Price Performance
Historical ComparisonAbout IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. The Company's primary business is exploring for, developing, and extracting gold, and to a lesser extent, silver, and base metal mineral resources in the greater Coeur d'Alene Mining District of North Idaho. The Company produces gold at the Golden Chest Mine located in the Murray Gold Belt area of the world-class Coeur d'Alene Mining District, north of the prolific Silver Valley.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.